The next 9 days may see a bit of a spike in anticipation of good news before the end of September:
-Successful clinical proof of concept funded by the Gates Foundation showed high accuracy for pneumonia and asthma diagnosis
-MulD-site clinical study progressing well with preliminary results due in Q3 CY2015
-FDA Pre-Submission mee'ng planned for Q4 CY2015 § Fully-funded to bring product to market in late 2016
I have recently taken a position and am excited by this Companys potential
RAP Price at posting:
2.7¢ Sentiment: Buy Disclosure: Held
